RxDoctor Payments Data

Edison Gavilanes, MD

Pulmonary Disease · Amityville, NYNPI 1992967731

Payments from drug & device makers

$15,718in general payments, 2019–2025

Across 542 payments — averaging $29.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • GSK$2K
  • Mallinckrodt Hospital Products Inc.$1K
  • Intra-sana Laboratories$967
  • Sanofi$767
  • Boehringer Ingelheim$743
  • plus $6K from 28 others

What the payments were for

  • Food & beverage$15,41298%
  • Education$3062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,718 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$659,808
Medicare patients
1,383
Services billed
5,598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter190$157,148
XolairOmalizumab20$69,587
Breo ElliptaFluticasone/Vilanterol133$67,229
NucalaMepolizumab13$55,672
Breztri AerosphereBudesonide/Glycopyr/Formoterol77$50,111
Incruse ElliptaUmeclidinium Bromide57$22,488
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$17,261
Bevespi AerosphereGlycopyrrolate/Formoterol Fum22$12,723
Spiriva RespimatTiotropium Bromide20$10,083
XareltoRivaroxaban11$8,846
SymbicortBudesonide/Formoterol Fumarate19$7,534
Albuterol Sulfate HfaAlbuterol Sulfate249$6,404
Arnuity ElliptaFluticasone Furoate20$5,872
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$3,676
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$3,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta$2,469$325,670449 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$3,899$70,368118 claims
Boehringer IngelheimSpiriva Respimat$743$10,08320 claims
Johnson & JohnsonXarelto$282$8,84611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Amityville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →